Mechanisms of histone methylation and acetylation modifying enzymes in ovarian cancer and therapeutic advances
10.12092/j.issn.1009-2501.2022.11.013
- Author:
Ling YUE
1
;
Junhong DU
1
;
Xiao LIU
1
;
Yulan LI
1
;
Feixue XU
2
Author Information
1. First Clinical Medical College of Lanzhou University
2. Department of Obstetrics and Gynecology, Key Laboratory of Gynecologic Oncology of Gansu Province, the First Hospital of Lanzhou University
- Publication Type:Journal Article
- Keywords:
epigenetic therapy;
histone modifying enzymes;
ovarian cancer;
precision oncology
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(11):1299-1306
- CountryChina
- Language:Chinese
-
Abstract:
Ovarian cancer is the most malignant gynecologic malignancy. In recent years, histone modifying enzymes (HMEs) have been widely studied as an important part of epigenetic modifi-cations in ovarian cancer. Histone modifying enzymes, including histone methyltransferases and demethylases, histone acetyltransferases and deacetylases, play an important role in the prolif-eration and migration of ovarian cancer cells by modifying histone and non-histone proteins, and can regulate the development of chemoresistance. Inhibitors of various histone modifying enzymes play good anti-tumor effects in ovarian cancer by promoting cell growth arrest and apoptosis, inhibi¬ting tumor cell invasion, and increasing chemo¬therapy sensitivity, and are expected to be a new strategy for precision treatment of ovarian cancer. Therefore, this paper will review the mechanism of action and therapeutic potential of histone modifying enzymes involved in methylation and acetylation processes in ovarian cancer.
